Answers are grounded in this paper and cite their sources.
DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.
No takes yet. Share an insight, caveat, or question.
Lozada et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: